Modality
siRNA
MOA
VEGFi
Target
TYK2
Pathway
Hedgehog
Dravet
Development Pipeline
Preclinical
~Nov 2021
→ ~Feb 2023
Phase 1
May 2023
→ Apr 2029
Phase 1Current
NCT05143426
206 pts·Dravet
2023-05→2029-04·Recruiting
206 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-04-043.0y awayPh2 Data· Dravet
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1/2
Recruit…
Catalysts
Ph2 Data
2029-04-04 · 3.0y away
Dravet
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05143426 | Phase 1/2 | Dravet | Recruiting | 206 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Gozeosocimab | Illumina | Phase 2 | BCMA | |
| COR-9566 | Corcept | Approved | TYK2 |